

NOW ENROLLING IN MUSCLE-INVASIVE BLADDER CANCER




PHASE 3 (NCT04209114)

PIVOT IO 009: Bempegaldesleukin with nivolumab for the neoadjuvant and adjuvant treatment of resectable muscle-invasive bladder cancer

A randomized study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy or standard of care for the neoadjuvant and adjuvant treatment of patients with cisplatin-ineligible resectable muscle-invasive bladder cancer¹

ENROLL NOW

Scan here to find out more about this clinical study at ClinicalTrials.gov



PRIMARY ENDPOINTS

- Pathologic complete response
- Event-free survival

SECONDARY ENDPOINTS

- Overall survival
- Safety and tolerability

Bempegaldesleukin is an investigational first-in-class CD122-preferential IL-2–pathway agonist²
Nivolumab is a PD-1 blocking antibody³

BEMPEG, bempegaldesleukin (NKTR-214); ECOG PS, Eastern Cooperative Oncology Group performance status; IL-2, interleukin-2; MIBC, muscle-invasive bladder cancer; NIVO, nivolumab.

1. ClinicalTrials.gov. NCT04209114. <https://clinicaltrials.gov/ct2/show/NCT04209114>. Accessed May 1, 2020. 2. Charych DH, et al. *Clin Cancer Res* 2016;22:680–690.

3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: May 2020).


CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB ARE NOW ENROLLING

NEKTAR

 Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverage two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE
Scan here to discover more about BEMPEG at Nektar.com



BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab.

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.